Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of AFTX-201 in BAG3 Dilated Cardiomyopathy.

Next Previous
Trial Profile

Clinical study of AFTX-201 in BAG3 Dilated Cardiomyopathy.

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AFTX-201 (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions
  • Acronyms UPBEAT trial

Most Recent Events

  • 07 Oct 2025 According to Affinia Therapeutics media release, Affinia expects to submit an Investigational New Drug (IND) application in the fourth quarter of 2025 and if accepted by the U.S. Food and Drug Administration (FDA), initiate the UPBEAT trial in the first quarter of 2026.
  • 07 Oct 2025 According to Affinia Therapeutics media release, company announced it has closed a $40 million Series C financing. The financing was led by New Enterprise Associates (NEA) with participation from new investor, Eli Lilly & Company, and existing investors Alexandria Venture Investments, LLC, Atlas Venture, Avidity Partners, F-Prime, GV (formerly Google Ventures), Mass General Brigham Ventures, and Perceptive Advisors.Financing supports IND submission and clinical activities.
  • 28 May 2025 According to Affinia Therapeutics ,the company is on a track to submit IND in fourth quarter of 2025 and nitial readouts of clinical trial safety and efficacy expected in the first half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top